论文部分内容阅读
目的:探讨生长抑素受体在复发、转移性乳腺癌癌组织中的表达情况及其临床意义。方法:对近5年来86例复发、转移乳腺癌切除转移病灶、转移灶旁组织和正常组织,进行生长抑素受体测定,将上述三组表达情况进行比较;同时与该86例患者第一次术后的生长抑素受体表达情况进行比较。结果:复发转移癌组织、癌旁组织及正常组织生长抑素受体表达率分别为25.58%-51.16%、2.33%-4.65%和0%;86例复发转移的癌组织与首次发病时的生长抑素受体表达率分别为38.37%和70.93%;P<0.05,有显著差异。结论:乳腺癌复发转移后癌组织中的生长抑素受体表达率明显低于首次发病时的表达率,此类患者病期晚、预后差,对于这类患者在应用生长抑素治疗前应力争获取癌组织,以便选择有效的辅助治疗方法。
Objective: To investigate the expression of somatostatin receptor in recurrent and metastatic breast cancer and its clinical significance. Methods: 86 cases of recurrent and metastatic breast cancer in the past 5 years were excised from the metastatic lesion, para-tumor tissue and normal tissue, and the somatostatin receptor was measured. The expression of these three groups were compared. At the same time, The postoperative somatostatin receptor expression was compared. Results: The expression rates of somatostatin receptor were 25.58% -51.16%, 2.33% -4.65% and 0% respectively in relapsed and metastasized cancer tissues, paracancer tissues and normal tissues. The recurrence and metastasis of 86 cancer tissues were similar to those of the first onset The expression rates of somatostatin receptor were 38.37% and 70.93%, respectively; P <0.05, there were significant differences. Conclusions: The expression of somatostatin receptor in breast cancer tissues after recurrence and metastasis was significantly lower than that at the first incidence. These patients had late stage and poor prognosis. For these patients, before somatostatin treatment, Strive to obtain cancer, in order to choose an effective adjuvant therapy.